BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.
- Home |
- BridgeBio preps approval push after dwarfism drug increases children’s height in phase 3
BridgeBio preps approval push after dwarfism drug increases children’s height in phase 3
- February 12, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
